AMGN · Q3 EPS $6.45, rev +8% YoY

Amgen reported Q3 2026 non-GAAP EPS of $6.45, beating the $5.78 consensus by 11.6%, and revenue of $10.365B, above the $10.06B consensus. Total revenue grew 8% YoY to $10.4B, driven by product sales growth of 8%, with 17 products delivering double-digit sales growth. The company raised its full-year 2026 non-GAAP EPS guidance to $22.90-$23.70 and revenue guidance to $38.9B-$39.7B, both above consensus expectations.

• Non-GAAP EPS $6.45 vs consensus $5.78 (beat by 11.6%)
• Total revenue $10.365B vs consensus $10.06B (beat by 3.0%)
• Total revenue grew 8% YoY to $10.4B
• Product sales grew 8% YoY to $9.883B